Calcipotriol
- Generic Name
- Calcipotriol
- Brand Names
- Calcitrene, Dovobet, Dovonex, Enstilar, Sorilux, Taclonex, Wynzora
- Drug Type
- Small Molecule
- Chemical Formula
- C27H40O3
- CAS Number
- 112965-21-6
- Unique Ingredient Identifier
- 143NQ3779B
- Background
Calcipotriol (INN) or calcipotriene (USAN) is a sythetic derivative of calcitriol or Vitamin D.
- Indication
For the treatment of moderate plaque psoriasis in adults.
- Associated Conditions
- Plaque psoriasis of the scalp, Psoriasis Vulgaris (Plaque Psoriasis)
- Associated Therapies
- -
Clinical utility of calcipotriene and betamethasone dipropionate for t
Cal/BD ointment, gel, foam, and cream formulations effectively treat plaque-type psoriasis, enhancing patient adherence and QoL. Cal/BD combinations offer rapid, high efficacy with minimal side effects, preventing skin atrophy and HPA axis disruption. These treatments are valuable for mild-to-moderate psoriasis, including in adolescents.
Related Clinical Trials:
Endo Partners with Paladin Pharma to Launch Wynzora Cream in Canada
Endo partners with Paladin Pharma to launch Wynzora® Cream in Canada, a topical treatment for plaque psoriasis, pending Health Canada approval.
Endo Announces Agreement for Paladin Pharma to Commercialize Wynzora® Cream in Canada
Endo, Inc. announced a definitive agreement with MC2 Therapeutics to commercialize Wynzora® Cream in Canada through Paladin Pharma Inc. Wynzora® Cream, approved by the FDA in 2020, is a topical treatment for plaque psoriasis, offering a convenient option for patients.
LEO Pharma continues to deliver double-digit revenue growth backed by strong dermatology sales
LEO Pharma reported 11% revenue growth in Q3 2024, with dermatology portfolio up 13%. Key milestones include European approval of Anzupgo® (delgocitinib) cream, NDA filing for delgocitinib in the U.S., and Enstilar® NDA in China. Full-year outlook remains unchanged.
Clariant to launch eight new high-performing excipients at the CPHI Milan 2024
Clariant introduces new health care products at CPHI Milan 2024, including VitiPure LEX 3350 S, VitiPure LEX 4000 S, and Polyglykol 1450 S, addressing API delivery and bioavailability challenges. VitiPure Superior line offers nearly colorless, highly-purified excipients for sensitive APIs and low microbial loads, while VitiPure HCO is developed for tablet formulations and topical applications.
Leo Pharma files for approval of psoriasis treatment Enstilar in China
Leo Pharma applies in China for approval of its psoriasis drug Enstilar for adult plaque psoriasis treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath